Mesothelioma Cancer Centers
The Rod Taylor Thoracic Care Center at Orlando Health UF Health Cancer Center is comprised of board-certified surgeons, medical and radiation oncologists, pathologists, radiologists, nurses, therapists and counselors.
The Rod Taylor Thoracic Care Center provides exceptional care from specifically trained thoracic surgeons who focus on care for patients with lung, esophageal and other cancers malignancies in the chest including, mesothelioma. The devoted, multidisciplinary healthcare team work together to evaluate and determine the most effective means of treatment for each patient.
Malignant pleural mesothelioma occurs as a rare, malignant tumor originating from mesothelial cells surrounding the lungs. The thoracic surgeons at the Rod Taylor Thoracic Care Center are specifically trained to perform advanced surgery of thoracic tumors and use the most minimally invasive techniques for diagnosing, staging and treating various thoracic cancers.
The center was a pioneer in Central Florida for using the minimally invasive lung surgery procedure, video-assisted thoracic surgery (VATS), and the robotic thoracic surgery known as the Da Vinci Surgical System. They were also the first hospital to perform routine CT screenings that detect lung cancers that are rarely presented on an X-ray.
- Integrative medicine
- LINX device
- Lung cancer screenings
- MRIdian treatment
- Radiation therapy
- Robotic thoracic surgery
- Thoracic cancer clinical trials
- American College of Surgeons (ACoS) Commission on Cancer Accreditation
- Florida Cancer Center of Excellence Award
- Lung Cancer Alliance Screening Center of Excellence
- Medical Oncology Certification
- Radiation Oncology Accreditation
Mesothelioma Clinical Trials at UF Health Cancer Center
The following clinical trials are in progress or actively recruiting participants at UF Health Cancer Center:
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Conditions: Advanced Malignancies; Metastatic Cancer Last Updated: June 19, 2019 Status: Recruiting
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Conditions: Mesothelioma; Uveal Melanoma; Renal Cell Carcinoma; Cholangiocarcinoma Last Updated: April 30, 2019 Status: Recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma Last Updated: January 16, 2019 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette